Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israel, Telavive
Veronika Chernuha
31 anos de experiência
Clínica certificada :
| Israel | Turquia | Áustria | |
| Terapia com Células Estaminais | de $7,500 | de $4,675 | de $8,500 |
| Plasmaférese | de $2,200 | de $1,200 | de $2,000 |
| Terapia com células estaminais para ELA (esclerose lateral amiotrófica) | - | de $30,000 | de $60,000 |
A Clínica Assuta é o maior centro médico privado de Israel. O hospital especializa-se em oncologia, ortopedia, neurocirurgia, cirurgia cardíaca e tratamento de infertilidade. 13% de todas as operações no país são realizadas na Assuta, o que a torna um centro cirúrgico líder.
Pela qualidade e segurança no tratamento, o hospital recebeu a acreditação americana da Joint Commission International.
Anualmente, os médicos da rede Assuta realizam mais de 92.000 operações, 685.000 procedimentos diagnósticos e 16.000 ciclos de FIV.
A Dra. Chernuha é especialista em neurologia pediátrica, com formação avançada em epilepsia resistente a medicamentos — oferecendo conhecimentos específicos para casos infantis complexos no Sourasky Medical Center.
Prof. Drory é especialista em ELA com 35 anos de experiência em neurologia – ela dirige a Unidade de Doenças Neuromusculares no Tel Aviv Sourasky Medical Center.
Neurologista pediátrico líder em Israel, especializado em distúrbios neurogenéticos no Sourasky Medical Center.
Como neurologista sénior no Centro Médico Hadassah, em Jerusalém, o Dr. Linecki traz mais de 23 anos de prática clínica dedicada.
Israel currently hosts advanced clinical trials for ALS, including the pivotal Phase 3 study of PrimeC and Phase 3b for NurOwn stem cell therapy. These trials target neuroinflammation and nerve regeneration at centers like Sourasky Medical Center and Hadassah Medical Center. Researchers also evaluate NG01 autologous stem cells and RNA-based gene therapies to slow disease progression.
Bookimed Expert Insight: Data shows Israel is a primary site for mutation-specific trials, particularly for SOD1 and rare genetic variants. Specialized clinics like the one led by Prof. Dr. Viviean Drory at Sourasky Medical Center blend these experimental protocols with 30+ years of electrophysiology expertise. This integration often allows patients to access innovative drugs 6–12 months before they reach broader international markets.
Patient Consensus: Patients note that early genetic testing is vital because many Israeli trials now require specific biomarker matches. They also emphasize that the enrollment process can take over 6 months, making early registration with hospital databases essential.
Standard ALS care in Israel utilizes Riluzole and Edaravone to slow disease progression. Specialist centers like Sourasky Medical Center (Ichilov) also offer Tofersen for patients with the SOD1 mutation. These medications are often combined with multidisciplinary symptomatic therapies to improve quality of life and respiratory function.
Bookimed Expert Insight: Data suggests that choosing high-volume centers like Sourasky Medical Center, which treats over 400,000 patients annually, provides better access to advanced protocols. Prof. Dr. Viviean Drory at this facility has over 35 years of experience in electrophysiological assessment. Such expertise is vital for the early diagnosis required to start Edaravone therapy effectively.
Patient Consensus: Patients note that while Riluzole is standard, the first month can involve side effects like nausea. Many emphasize requesting the Riluzole and Edaravone combination early to maximize stability.
Israel hosts premier multidisciplinary ALS centers at Sourasky Medical Center, Hadassah Medical Center, and Sheba Medical Center. These facilities utilize a one-stop-shop model. Patients access neurologists, respiratory therapists, and physical therapy in single visits. Leading specialists like Prof. Dr. Vivian Drory provide expert care.
Bookimed Expert Insight: Israeli ALS centers stand out because they integrate research directly into clinical care. For example, Hadassah Medical Center acts as a global leader in genetic research and stem cell trials. While Sourasky (Ichilov) remains a top choice for international patients due to its high ranking in Newsweek, its experts like Prof. Dr. Vivian Drory bring over 35 years of specialized experience. This combination of high-volume clinical practice and active scientific discovery often allows patients to access experimental protocols earlier than in many other regions.
Patient Consensus: Patients note that these centers provide remarkably fast access to specialized teams including pulmonologists and nutritionists. Many value the integrated speech therapy and ventilator support at Ichilov for significantly improving daily quality of life.
International patients can enroll in Israeli ALS clinical trials subject to Ministry of Health approval and specific study quotas. Participation often requires self-funding for experimental treatments. Prominent centers like Hadassah Medical Center and Tel Aviv Sourasky Medical Center (Ichilov) frequently host global trials for stem cell and gene therapies.
Bookimed Expert Insight: Data from major Israeli facilities shows a high concentration of ALS research in Tel Aviv and Jerusalem. While Ichilov serves over 400,000 patients annually, its specialized neuromuscular department often prioritizes patients based on progression rates. Patients should look for trials with expanded access labels. These typically offer more flexibility for those traveling from outside the European Union or North America.
Patient Consensus: Patients emphasize the need to budget for significant travel and lodging costs during long-term trials. Many recommend prioritizing centers that provide English-language consent forms to avoid extra translation hurdles during the screening process.